Compare Roblox Corp (RBLX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs Twist Bioscience Corp — how do they compare? Roblox Corp trades at $48.71 (market cap $32.52B), while Twist Bioscience Corp trades at $162.26 (market cap $10.08B). The key difference: Roblox Corp is far larger — about 3.2× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roblox Corp for 93 Days and Twist Bioscience Corp for 27 Days on average.
| RBLX | TWST | |
|---|---|---|
Market Cap | $32.52B | $10.08B |
Volume | 14,552,045 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $138.56 | $205.00 |
52-Week Low | $35.54 | $25.45 |
Typical Hold Time | 93 Days | 27 Days |
Enterprise Value | $31.34B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Roblox (RBLX) trades at $48.74, up 5.02% in the last session, with technical indicators showing bearish momentum despite recent price strength. The company continues to demonstrate strong revenue growth, reaching $4.89 billion in 2025, but remains unprofitable with a net income margin of -17.61%. Recent analyst downgrades from Jefferies highlight concerns about bookings growth, while AI development tools show potential for long-term platform expansion.
The stock faces near-term headwinds from bearish technical signals and valuation concerns, but strong revenue growth and AI innovation provide long-term potential. Key risks include persistent profitability challenges and competitive pressures in the gaming sector, while analyst consensus suggests modest upside to the $50.85 price target.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
